medigraphic.com

2008, Number 4

<< Back Next >>

Arch Cardiol Mex 2008; 78 (4)

Primary and secondary prevention of sudden cardiac death in the ICD Registry-Latin America

Ramos JL, Muratore C, Pachón MJC, Rodríguez A, González HA, Asenjo R, Rodríguez D, Galvao S, Duque M, Escudero J, Reyes CW, Cuvillier E, Maloney J

Language: Spanish
References: 17
Page: 400-406
PDF size: 130.85 Kb.


ABSTRACT

Introduction and objectives: The ICD Registry is an observational study conducted in Latin America to collect data on indications and follow-up care for primary or secondary prevention of sudden cardiac death patients. The objective of this study is to compare and evaluate the characteristics of primary versus secondary prevention in the patient population enrolled in the registry. Methods: Demographic data, indication, etiology, NYHA functional class and left ventricular ejection fraction (LVEF), pharmacological treatment at implant and the type of ICD implanted were also collected. During the follow-up period the ICD therapies delivered, patient hospitalizations and mortality were evaluated. Results: 507 patients were evaluated. Average age 60 ± 14 years old, 78% male. Coronary heart disease was the most common etiology (43.6%). NYHA Functional Class I/II at the time of implant (73.6%). Average LVEF was 34 ± 16%. Out of 507 patients, 189 received an ICD for primary prevention; 318 for secondary prevention. Primary prevention patients were older, predominantly male and had a lower EF. The rate of mortality and hospitalizations were similar between both groups with a higher rate of appropriate therapies in secondary prevention patients. Conclusions: This is the first study to demonstrate clinical characteristics of primary prevention patients in Latin America. There were no significant statistically differences in a short follow-up period in mortality or hospitalization as compared to the secondary prevention patient population in the Registry. (Arch Cardiol Mex 2008; 78: 400-406)


REFERENCES

  1. The antiarrhythmics versus implantable defibrillator (AVID) investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337: 1576-1583.

  2. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, Mitchell LB, et al: Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297-1302.

  3. Kuck KH, Cappato R, Siebels J, Ruppel R: Randomized comparison of antiarrhythmia drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748-754.

  4. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, et al: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.

  5. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, et al: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237.

  6. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, et al: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.

  7. Zipes DP, Camm J, Borggrfe M, Buxton AE, Chaitman B, Fromer M et al: Ventricular Arrhythmias and Prevention of Sudden Cardiac Death. Rev Esp Cardiol 2006; 59(12): 1328.

  8. ACC/AHA/ESC 2006 Guidelines for management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death-Executive Summary. JACC 2006; 48: 1064-1108.

  9. Proclemer A, Ghidina M, Cicuttini G, Gregori D, Fioretti PM: Impact of the Main Implantable Cardioverter-Defibrillator Trials for Primary and Secondary Prevention in Italy: A Survey of the National Activity During the Years 2001–2004. PACE 2006; 29 (Suppl 2): S20-S28.

  10. Dubner S, Valero E, Pesce R, Zuelgaray JG, Mateos JC, Filho SG, Reyes W et al: A Latin American registry of implantable cardioverter defibrillators: the ICD-LABOR study. Ann Noninvasive Electrocardiol. 2005; 10(4): 420-8.

  11. Greenberg SM, Epstein AE, Deering T, Goldman DS, Ghidina M, Neason C, Proclamer A: A Comparison of ICD Implantations in the United States Versus Italy. Pacing Clin Electrophysiol 2007; 30 (Suppl 1): S143-6.

  12. Danish Pacemaker and ICD Register. www. pacemaker.dk. 2004.

  13. Peinado R, Arenal A, Arribas F, Torrecilla E, Alvarez M Ormaetxe JM, Perez-Castellano N: Spanish implantable cardioverter-defibrillator registry. First official report of the spanish society of cardiology working group on implantable cardioverter-defibrillators(2002-2004). Rev Esp Cardiol 2005; 58(12): 1435-49.

  14. Havranek E, Masoudi F, Westfall K, Wolfe P, Ordin DL, Krumholz HM: Spectrum of heart failure in older patients: results from the National Heart Failure project. Am Heart J 2002; 143(3): 412-7.

  15. The DAVID trial investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. JAMA 2002; 288(24): 3115-3123.

  16. Moss AJ: MADIT-II: substudies and their implications. Card Electrophysiol Rev 2003; 7(4): 430-3.

  17. EVADEF investigators. EVADEF Registry, main data. Arch Mal Coeur Vaiss 2007; 100(2): 99-103.




2020     |     www.medigraphic.com